Mechanisms of atherothrombosis in chronic obstructive pulmonary disease by Filippo Luca Fimognari et al.
© 2008 Dove Medical Press Limited.   All rights reserved
International Journal of COPD 2008:3(1) 89–96 89
REVIEW
Mechanisms of atherothrombosis in chronic 
obstructive pulmonary disease
Filippo Luca Fimognari1,2
Simone Scarlata1
Maria Elisabetta Conte1
Raffaele Antonelli Incalzi1
1Health Centre for Elderly, Chair 
of Geriatrics, University Campus 
Bio Medico, Rome, Italy; 2Internal 
Medicine; ASL Roma G, Leopoldo 
Parodi-Delfino Hospital; Colleferro, 
Rome, Italy
Correspondence: Simone Scarlata
Chair of Geriatrics, Centro per la salute 
dell’anziano (CeSA), Via dei Compositori, 
130 00128 Rome, Italy
Tel +39 06 2254 1648
Fax +39 06 2254 1602
Email s.scarlata@unicampus.it
Abstract: Patients affected by chronic obstructive pulmonary disease (COPD) have an increased 
risk of atherothrombotic acute events, independent of smoking and other cardiovascular risk 
factors. As a consequence, myocardial ischemia is a relevant cause of death in these patients. 
We reviewed studies concerning the potential mechanisms of atherothrombosis in COPD. 
Bronchial inﬂ  ammation spreads to the systemic circulation and is known to play a key role in 
plaque formation and rupture. In fact, C-reactive protein blood levels increase in COPD and 
provide independent prognostic information. Systemic inﬂ  ammation is the ﬁ  rst cause of the 
hypercoagulable state commonly observed in COPD. Furthermore, hypoxia is supposed to 
activate platelets, thus accounting for the increased urinary excretion of platelet-derived throm-
boxane in COPD. The potential metabolic risk in COPD is still debated, in that recent studies 
do not support an association between COPD and diabetes mellitus. Finally, oxidative stress 
contributes to the pathogenesis of COPD and may promote oxidation of low-density-lipoproteins 
with foam cells formation. Retrospective observations suggest that inhaled corticosteroids may 
reduce atherothrombotic mortality by attenuating systemic inﬂ  ammation, but this beneﬁ  t needs 
conﬁ  rmation in ongoing randomized controlled trials. Physicians approaching COPD patients 
should always be aware of the systemic vascular implications of this disease.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide 
(Calverley and Walker 2003). In addition to the healthcare costs, COPD imposes a 
signiﬁ  cant burden in terms of disability and impaired quality of life. Unlike many other 
leading causes of death and disability, COPD prevalence will raise in the majority of 
countries as smoking frequency increases and the population ages (Halbert et al 2006). 
The World Health Organization predicts that by 2020 COPD will be the 5th most 
prevalent disease worldwide (presently the 12th) and the 3th most common cause of 
death (presently the 6th). Not respiratory outnumber respiratory causes of death, and 
most of them are cardiovascular causes (Hansell et al 2003). This is the rationale for 
reviewing the main mechanisms of the COPD-related atherothrombotic risk.
We performed a series of MEDLINE database searches for English language 
literature published from 1970 to April 2007 by combining the medical subject head-
ing (MeSH) terms chronic obstructive pulmonary disease, chronic bronchitis and 
pulmonary emphysema with the following MeSH terms atherosclerosis, thrombosis, 
platelet activation, platelet aggregation, thromboxane, inﬂ  ammation, inﬂ  ammation 
mediators, C-reactive protein, blood coagulation, blood coagulation mediators, 
blood coagulation factor inhibitors, corticosteroids, catecholamines, sympathetic 
nervous system, oxidative stress, isoprostanes, F2 isoprostanes. We also supple-
mented references by cross-checking bibliographies of retrieved articles to identify 
additional studies.International Journal of COPD 2008:3(1) 90
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COPD and atherothrombotic risk: 
the epidemiological evidence
Reduced forced expiratory volume in 1 second (FEV1) was 
associated with increased pulse wave velocity, a surrogate 
measurement for central arterial stiffness, endothelial dys-
function and atherosclerosis (Zureik et al 2001).
Although not generally recognized, a low FEV1 has been 
shown to be as powerful a predictor of cardiac mortality as total 
serum cholesterol, irrespective of the effect of smoking and other 
possible confounders (Hole et al 1996). In a recent meta-analysis 
(Sin et al 2005b), the relative risk of cardiovascular death in the 
group with the lowest FEV1 compared with that with the high-
est FEV1 was 3.36 (1.54–7.34); the corresponding ﬁ  gure for 
mortality due to myocardial ischemia was 5.65 (2.26–14.13). 
As a consequence, coronary artery disease is one of the leading 
causes of death in COPD patients (Hansell et al 2003).
FEV1/forced vital capacity (FEV1/FVC) ratio, a more 
sensitive parameter of obstructive disease than FEV1, was 
also found to be independently related to vascular events 
(Engstrom et al 2001).
The overall atherothrombotic impact of COPD is further 
proved by the increased risk of ischemic stroke in COPD 
patients. In a 15-year follow up, the relative risk of fatal 
stroke was 1.1 (1.03–1.2) for every 10% decrease of FEV1 
(Truelsen et al 2001).
Pro-atherothrombotic mechanisms 
in COPD
The mechanisms responsible for the association between 
COPD and atherothrombosis are still largely unknown. 
However, at least four factors seem to be pathogenetically 
important: chronic systemic inﬂ  ammation, hypercoagulable 
state, platelet activation and oxidative stress (Figure 1).
Systemic inﬂ  ammation (Table 1)
In the context of the complex and multifactorial pathogen-
esis of atherothrombosis, low grade systemic inﬂ  ammation 
is believed to be a crucial mechanism in plaque formation 
and rupture (Pasceri et al 2000). This concept is strongly 
supported by experiments showing that some inﬂ  ammatory 
markers, such as C-reactive protein (CRP) and ﬁ  brinogen, 
are implicated in plaque formation. CPR upregulates the 
production of pro-inﬂ  ammatory cytokines and tissue factor 
by monocytes, increases the uptake of low-density lipopro-
teins (LDL) by macrophages with foam cells formation and 
directly induces expression of adhesion molecules by human 
endothelial cells (Pasceri et al 2000).
Alveolar macrophages, bronchial epithelial cells and 
lymphocytes, which are implicated in bronchial and alveolar 
inﬂ  ammation, produce interleukin (IL)-6 and IL-1β. These 
cytokines, besides inducing local pro-inﬂ  ammatory changes, 
“spill-over” into the systemic circulation and stimulate hepa-
tocytes to synthesize CRP and ﬁ  brinogen. Accordingly, sys-
temic blood concentrations of tumor necrosis factor (TNF)-α, 
IL 6, IL 8, CRP and ﬁ  brinogen are higher in COPD than in 
control subjects (Gan et al 2004). Interestingly, at variance 
from the response observed in healthy subjects and diabetic 
patients, moderate-intensity exercise abnormally increases 
plasma TNF-α levels in COPD patients (Rabinovich et al 
2003; Zoppini et al 2006). Circulating TNF-α levels have 
been found to increase in malnourished COPD patients, 
likely because systemic hypoxia stimulates TNF-α synthesis 
(Takabatake et al 2000). TNF-α can cause the expression 
of tissue factor on monocytes and, possibly, endothelium, 
thereby initiating the coagulation cascade (Esmon 2000).
CRP serum levels have also been found to increase for 
increasing severity of bronchial obstruction, ie, in COPD, 
the level of “systemic” inﬂ  ammation (CRP) strictly paral-
lels that of “local” bronchial inﬂ  ammation and obstruction 
(FEV1) (Sin and Man 2003). In addition, COPD patients 
with high CRP serum levels have increased risk of either 
atherothrombotic events (fatal and nonfatal coronary artery 
disease and stroke) or all-cause mortality, after adjusting for 
age, sex, smoking and lung function (Man et al 2006). These 
recent data support the role of the systemic inﬂ  ammation in 
the development of atherothrombotic disorders in COPD. 
In addition, they suggest that CRP measurements should be 
considered in prognostic models for COPD patients.
Pulmonary hypertension is highly prevalent also in nonhy-
poxemic COPD and predicts a poor prognosis (Weitzenblum 
et al 1981). In a recent study, CRP and hypoxia were the only 
signiﬁ  cant correlates of systolic pulmonary arterial pressure, 
suggesting that systemic inﬂ  ammation may be involved in 
the pathogenesis of COPD-related pulmonary hypertension 
(Joppa et al 2006).
Hypercoagulable state (Table 2)
Some case-control studies have clearly established that, inde-
pendent of current smoking, plasma levels of ﬁ  brinogen and 
other markers of coagulation are signiﬁ  cantly higher in stable 
COPD patients than in healthy subjects (Alessandri et al 
1994; Xie and Wang 1998; Wedzicha et al 2000; Ashitani 
et al 2002). The increased procoagulant activity in COPD 
may primarily result from inﬂ  ammation. In fact, inﬂ  amma-
tion can trigger coagulation by promoting tissue-factor gene International Journal of COPD 2008:3(1) 91
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expression in endothelial cells (Esmon 2000; Libby 2001). 
Hypoxia also could either reduce endothelial thrombo-
modulin expression or activate factor X (Ogawa et al 1990). 
Coagulation, in turn, ampliﬁ  es inﬂ  ammation and both are 
strongly implicated in the pathogenesis of atherothrombosis 
(Libby and Simon 2001). That a pro-coagulant status may 
promote atherothrombosis in COPD is suggested by the direct 
relationship between serum ﬁ  brinogen and the incidence of 
cardiovascular events in the general population (Danesh et al 
1998). Interestingly, central pulmonary lesions, indicative of 
in situ thrombosis and atherosclerosis, are common in stable 
COPD patients even free from pulmonary hypertension, and 
their extent is not strictly related to the severity of bronchial 
obstruction (Russo et al 1999). This ﬁ  nding testiﬁ  es to a 
procoagulant and proatherosclerotic status which can be 
recognized early in the course of COPD.
Importantly, ﬁ  brinogen levels rise further during COPD 
exacerbation (Wedzicha et al 2000). The acute release of this 
and other prothrombotic factors may thus account for the 
increased rate of myocardial infarctions immediately follow-
ing low-respiratory tract infections (Meier et al 1998).
Platelet activation (Table 3)
The role of platelet in atherothrombosis is clearly supported by 
the efﬁ  cacy of aspirin and other antiplatelet drugs in prevent-
ing vascular events in the general population (Patrono et al 
2004). Earlier studies had showed increased platelet aggre-
gability in hypoxaemic COPD patients (Cordova et al 1985; 
Figure 1 The COPD-atherothrombosis network.
Table 1 Mechanisms of systemic inﬂ  ammation in COPD
References  Type of study  Main evidence
Pasceri et al 2000  Basic research  CPR upregulates the production of pro-inﬂ  ammatory cytokines and tissue factor by monocytes.
    It increases the uptake of LDL by macrophages with foam cells formation and directly induces
    expression of adhesion molecules by human endothelial cells.
Sin et al 2003  Population-based  CRP is increased in COPD.
Man et al 2006  Population-based  CRP is a prognostic factor in COPD.
Joppa et al 2006  Cross-sectional  Systemic inﬂ  ammation might be pathogenetically related to pulmonary hypertension
   complicating  COPD.
Gan et al 2004  Meta-analysis  Serum levels of TNF-α, IL 6, IL 8, CRP, and ﬁ  brinogen are increased in COPD.
Abbreviations: COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; LDL, low-density lipoprotein; TNF-α, tumor necrosis factor-alpha; IL 6, interleukin-6; 
IL 8, interleukin-8.International Journal of COPD 2008:3(1) 92
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Wedzicha et al 1991). More recently, platelet aggregation has 
been studied in vivo by measuring 11-dehydro-thromboxane 
B2 (11-d-TxB2), the urinary metabolites of TxA2 (Patrono 
et al 1995). This eicosanoid is generated by activated platelets 
through the enzyme cyclooxygenase-1, which is speciﬁ  cally 
inhibited by aspirin. Once released, TxA2 ampliﬁ  es platelet 
aggregation and stimulates smooth muscle constriction and 
proliferation (Rolin et al 2006). TxA2 is also a strong constrictor 
of bronchial smooth muscle cells and has been involved in the 
pathogenesis of asthma (Tamaoki et al 2000). The measurement 
of urinary 11-d-TxA2 directly reﬂ  ects biosynthesis and is there-
fore a measure of platelet function (Patrono et al 1995). High 
excretory values identify patients at increased risk of myocar-
dial infarction and cardiovascular death (Eikelboom et al 2002). 
Importantly, urinary 11-d-TxB2 values are signiﬁ  cantly greater 
in patients with stable COPD than in control subjects, irrespec-
tive of smoking status, inversely correlated with arterial oxygen 
tension and are signiﬁ  cantly lowered by short – term oxygen 
supplementation (Davì et al 1997). These data suggest a link 
between hypoxia and platelet activation likely because hypoxia 
induces metabolic changes on the platelet membrane, leading 
to increased activation of cyclooxygenase-1 with thromboxane 
formation (Ponicke et al 1987). In addition, platelet stimulation 
may result from clotting activation with thrombin generation, 
that, in turn, is well known to enhance platelet thromboxane 
biosynthesis (Patrono 1990).
Oxidative stress (Table 4)
The development of COPD is associated with oxidative 
stress and reduced antioxidant properties (Boots et al 2003). 
Hydrogen peroxide (H2O2) in exhaled breath condensate is a 
marker of oxidative stress in the lungs and have been found 
to be elevated in COPD patients irrespective of smoking 
status (Dekhuijzen et al 1996; Nowak et al 1999), as well as 
in smokers without the disease (Nowak et al 2001). Oxida-
tive stress can promote the peroxidation of polyunsaturated 
fatty acids. Thiobarbituric acid-reacting substances represent 
a measure of such a lipid peroxidation and are increased in 
exhaled breath condensate of patients with COPD (Nowak 
et al 1999).
Pulmonary oxidative stress “spreads out” to the circula-
tion and becomes a systemic alteration (Boots et al 2003). 
F2-isoprostanes are stable products of peroxidation of arachi-
donic acid (Delanty et al 1996). The assay of F2-isoprostanes 
in the urine is a reliable measure of in vivo, systemic oxidative 
stress and, more importantly, it is a marker of LDL oxida-
tion (Devaraj et al 2001), that, in turn, is a key event in the 
pathogenesis of atherosclerosis (Berliner and Heinecke 1996; 
Patrono et al 2004). Independently of current smoking, the 
excretion of F2-isoprostane increases signiﬁ  cantly in COPD 
and peaks during exacerbations (Praticò et al 1998). This 
should suggest a LDL oxidative susceptibility in COPD, an 
abnormality potentially contributing to plaque formation.
Table 2 Mechanisms explaining the procoagulant status which characterizes COPD (see also Table 3)
References  Type of study  Main evidence
Ogawa et al 1990  Basic research  Hypoxia dynamically modulates endothelial function. The ensuing endothelial dysfunction
    might promote microvascular lesions.
Alessandri et al 1994,  Case-control  COPD patients have an ongoing prothrombotic state
Ashitani et al 2002 and  Case-control  which might explain the high prevalence of
Xie et al 1998  Case-control  thrombosis in pulmonary vessels.
Wedzicha et al 2000  Prospective  Fibrinogen levels, which are basically higher than normal, further raise during
   COPD  exacerbation.
Danesh et al 1998  Meta-analysis  High levels of serum ﬁ  brinogen reliably predicts cardiovascular events
    in the general population.
Abbreviation: COPD, chronic obstructive pulmonary disease.
Table 3 Epidemiological evidence and mechanisms of platelet hyperaggregability in COPD
References  Type of study  Main evidence
Ponicke et al 1987  Basic research  Hypoxia induces metabolic changes on the platelet membrane, leading to increased
    activation of cyclooxygenase-1 with thromboxane formation.
Davì et al 1997  Case-control  Thromboxane excretion is increased in COPD, inversely correlates with oxygen tension
    and is signiﬁ  cantly lowered by short-term oxygen supplementation.
Cordova et al 1985;   Case-control  Increased platelet aggregability in hypoxemic COPD patients.
Wedzicha et al 1991
Abbreviation: COPD, chronic obstructive pulmonary disease.International Journal of COPD 2008:3(1) 93
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Lipid status and metabolic risk in COPD 
(Table 5)
The increased vascular risk in COPD cannot be attributed to 
an atherogenic lipid pattern. In COPD patients, lipid levels 
are comparable with those measured in healthy subjects, 
with values of lipoprotein(a) and of APO B-100 being even 
signiﬁ  cantly lower (Basili et al 1999).
The relation between diabetes mellitus, one of the leading 
atherothrombotic factors, and COPD is unclear. There are 
data supporting the notion that the lung is a target organ in 
diabetes, but abnormalities mostly include alveolar microan-
giopathy with impaired diffusion capacity (Hsia and Raskin 
2005) and a restrictive ventilatory dysfunction (Lawlor et al 
2004). Results of prospective observations in COPD patients 
are confounding. In a study, COPD was a risk factor for the 
onset of type 2 diabetes mellitus, but spirometric diagnostic 
data were not reported (Rana et al 2004). In another study, 
an obstructive pattern was not associated with the develop-
ment of diabetes, that, conversely, was signiﬁ  cantly increased 
in subjects with a restrictive ventilatory pattern (Ford and 
Mannino 2004). Accordingly, metabolic syndrome and 
insulin-resistance were very frequent in nondiabetic sub-
jects with restrictive dysfunction, but not in COPD patients 
(Fimognari et al 2007).
Neurohumoral activation
There are convincing data demonstrating a COPD-related 
neurohumoral activation, including sympathetic overactiv-
ity, increased release of catecholamines and decreased vagal 
tone (Andreas et al 2005). This alteration is evident also after 
interruption of medications for COPD (Scalvini et al 1999) 
and is supposed to contribute to a generic cardiovascular and 
systemic risk in COPD (arrhythmias, cachexia, muscle wast-
ing with fatigue) (Andreas et al 2005). The speciﬁ  c impact 
of neurohumoral activation on the atherothrombotic status 
of COPD, however, is unclear.
Animal models showed that sympathetic activation 
can promote systemic inﬂ  ammation (Woiciechowsky et al 
1998; Borovikova et al 2000; Li et al 2004). Theoretically, 
the neurohumoral activation occurring in COPD may thus 
favour atherothrombosis by stimulating systemic and vas-
cular inﬂ  ammation, but this potential causative association 
needs to be proven in patients with COPD.
Another mechanism by which the sympathetic activa-
tion may promote atherothrombosis in COPD is platelet 
activation. It is well known that the catecholamines released 
during acute stress may directly activate platelets (Hjemdahl 
et al 1991, 1994; Larsson et al 1994), but there are no data 
to demonstrate that this may also take place during chronic 
neurohumoral activation, like that complicating COPD 
(Fimognari et al 1996). In conclusion, the notion that the 
neurohumoral activation contributes to the COPD-related 
platelet hyperfunction is still highly speculative.
Potential therapies (Table 6)
The role of systemic inﬂ  ammation in precipitating vascular 
events in COPD is strongly supported by accumulating data 
showing the potential beneﬁ  ts of inhaled corticosteroids. 
These drugs, commonly used to attenuate lung inﬂ  amma-
tion, have been demonstrated to reduce plasma CRP levels in 
stable COPD, suggesting a “cooling” effect also on systemic 
inﬂ  ammation (Sin et al 2004; Pinto-Plata et al 2006). In a 
Table 4 Potential mechanisms of oxidative stress in COPD
References  Type of study  Main evidence
Devaraj et al 2001  Basic research  The assay of prostaglandin-like compounds in the urine is a reliable measure of in vivo oxidative
    stress and represents a marker of LDL oxidation.
Praticò et al 1998  Case-control  Independently of current smoking, the excretion of F2-isoprostane is increased in COPD
    and peaks during exacerbations.
Abbreviations: LDL, low-density lipoprotein; COPD, chronic obstructive pulmonary disease.
Table 5 Lipid status and metabolic risk in COPD
References  Type of study  Main evidence
Basili et al 1999  Case-control  COPD patients and healthy subjects have comparable lipid levels.
Rana et al 2004  Prospective  COPD might be a risk factor for incident type 2 diabetes mellitus.
Ford et al 2004  Prospective  Restrictive, but not obstructive, subjects are at increased risk of developing type 2 diabetes mellitus.
Fimognari et al 2007  Population-based  Metabolic syndrome and insulin-resistance are highly prevalent in nondiabetic subjects
    with restrictive dysfunction, but not in COPD patients.
Abbreviation: COPD, chronic obstructive pulmonary disease.International Journal of COPD 2008:3(1) 94
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recent meta-analysis of randomized controlled trials (RCTs), 
the mortality of COPD patients on inhaled corticosteroids was 
27% lower than that reported in the placebo group (adjusted 
hazard ratio, 0.73; 95% conﬁ  dence interval, 0.55–0.96) (Sin 
et al 2005a). Of note, this is the same mortality reduction 
obtained by a 3-year therapy with simvastatin in the Scandi-
navian Simvastatin Survival Study (Scandinavian Simvastatin 
Survival Study Group 1994). Because the trials included in 
the meta-analysis were not planned to test the effect of inhaled 
steroids on survival, the result needs to be conﬁ  rmed in RCTs 
speciﬁ  cally designed for this aim. However, the improved 
survival may be due to a reduction in cardiovascular deaths, 
in turn determined by the effect of inhaled corticosteroids on 
vascular plaque inﬂ  ammation. This intriguing hypothesis is 
suggested by some important observational studies. Huiart 
and collegues (2005) found a 18% nonsigniﬁ  cant reduction 
of myocardial infarctions amongst users of inhaled cortico-
steroids, but in a subgroup of patients taking 50–200 µg/day 
of steroids the risk reduction increased to 32% (p  0.05). A 
recent study, while conﬁ  rming improved survival in cortico-
steroid users (Macie et al 2006), found that this beneﬁ  t largely 
derived from a 38% reduction in cardiovascular mortality, 
while the reduction in respiratory deaths was nonsigniﬁ  cant. 
Recently, the EUROSCOP (European Respiratory Society 
Study on Chronic Pulmonary Disease) trial reported a 40% 
reduction in the rate of coronary artery disease events in 
patients taking inhaled corticosteroids compared to the pla-
cebo group (Lofdahl et al 2005).
Very recently, the effect on mortality of inhaled cortico-
steroids has been questioned by the results of an important 
RCT, the TORCH (Toward a Revolution in COPD Health) 
study (Calverley et al 2007). The mortality rate at 3 years in 
the ﬂ  uticasone group (16%) was comparable to that observed 
in the placebo group (15.2%). In patients treated with the 
combination therapy of ﬂ  uticasone plus the long-acting 
β2-agonist salmeterol (mortality rate:12.6%) there was an 
interesting 17.5% reduction in the risk of death compared 
with placebo, with a nonsigniﬁ  cant difference (p = 0.052). 
The impact of these drugs on cardiovascular mortality only 
was not reported. It is possible that the combination therapy 
does improve survival in COPD patients and that this study 
was underpowered to detect this effect. In addition, because 
β2-agonists activate glucocorticoid receptors in the lung 
(Eickelberg et al 1999), the association with β2-agonists may 
be crucial to highlight any effect of inhaled corticosteroids 
on mortality.
The only treatment improving survival in COPD is long-
term oxygen therapy in hypoxemic patients (Afessa et al 
2002). Oxygen therapy may prevent the hypoxia-induced 
platelet activation and blood clotting, and part of its clinical 
beneﬁ  t may come from a reduction of atherothrombotic fatal 
events by these effects. Furthermore, oxygen supplementa-
tion prevents exercise-induced oxidative stress in normox-
emic, muscle-wasted patients with COPD (van Helvoort et al 
2006). However, short-term oxygen supplementation has 
also been reported to promote oxidative stress and airway 
inﬂ  ammation (Carpagnano et al 2004).
Conclusion
COPD is now recognized as a systemic inﬂ  ammatory disease 
that may adversely affect the arterial district, predisposing 
patients to an increased risk of atherosclerotic plaque for-
mation and rupture. Systemic inﬂ  ammation plays a leading 
role in this process, but other mechanisms, such as platelet 
activation, coagulation and oxidative stress, can promote 
atherosclerosis in COPD. Research is needed to further 
Table 6 Potential therapies of systemic inﬂ  ammation in COPD
References  Type of study  Main evidence
Sin et al 2004  Randomized placebo-control  Inhaled corticosteroids reduce plasma CRP levels in stable COPD.
Pinto-Plata et al 2006  Cross-sectional analysis  “Cooling” effect of inhaled corticosteroids on systemic inﬂ  ammation.
Huiart et al 2005  Observational  COPD patients taking 50–200 µg/day of inhaled steroids
    have a 32% fall of the risk of myocardial infarction.
Macie et al 2006  Observational  Reduction in cardiovascular mortality by 38% accounts for the improved
    survival associated with chronic use of inhaled steroids.
Sin et al 2005  Pooled analysis from 7 RCT’s  27% mortality decrease in COPD patients taking inhaled corticosteroids.
Lofdahl et al 2005  RCT  40% reduction in the rate of coronary artery disease events after therapy
    with inhaled budesonide compared with the placebo group.
Cochrane 2005  Meta-analysis  The only evidence-based treatment improving survival is long-term
    oxygen therapy in hypoxemic patients.
    To note: Oxygen has antioxidant and anti-inﬂ  ammatory
    activity in hypoxemic COPD.
Abbreviations: CRP, C-reactive protein; COPD, chronic obstructive pulmonary disease; RCT, randomized controlled trials.International Journal of COPD 2008:3(1) 95
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clarify mechanisms of atherothrombosis, as well as to iden-
tify therapeutic and preventive strategies. Current evidence 
is consistent with an optimal care of bronchial inﬂ  ammation 
likely translating in some reduction of atherothrombotic risk. 
However, the very early development of the pro-atherothrom-
botic status in the course of COPD suggests that researchers 
should think of COPD as of a systemic disease from its onset. 
Accordingly, patients should receive advice about nonrespi-
ratory effects of COPD. This communication strategy might 
improve the awareness of the disease status and of the need 
of halting its progression by the most important preventive 
measure: smoking cessation.
Eventually, the evidence of systemic effects of COPD 
should induce pneumologists to have a multidisciplinary 
and multidimensional approach to the disease by involving 
various specialists. The relatively poor progress in the treat-
ment of COPD in the second half of the last century, when 
compared with therapy of other chronic diseases, likely 
reﬂ  ects the purely respiratory-centered, then scotomic, view 
of the disease.
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